Quantitative imaging of intracellular nanoparticle exposure enables prediction of nanotherapeutic efficacy

Qingqing Yin, Anni Pan, Binlong Chen, Zenghui Wang, Mingmei Tang, Yue Yan, Yaoqi Wang, Heming Xia, Wei Chen, Hongliang Du, Meifang Chen, Chuanxun Fu, Yanni Wang, Xia Yuan, Zhihao Lü, Qiang Zhang, Yiguang WangNature Communications 2021 · DOI

Abstract

Nanoparticle internalisation is crucial for the precise delivery of drug/genes to its intracellular targets. Conventional quantification strategies can provide the overall profiling of nanoparticle biodistribution, but fail to unambiguously differentiate the intracellularly bioavailable particles from those in tumour intravascular and extracellular microenvironment. Herein, we develop a binary ratiometric nanoreporter (BiRN) that can specifically convert subtle pH variations involved in the endocytic events into digitised signal output, enabling the accurately quantifying of cellular internalisation without introducing extracellular contributions. Using BiRN technology, we find only 10.7-28.2% of accumulated nanoparticles are internalised into intracellular compartments with high heterogeneity within and between different tumour types. We demonstrate the therapeutic responses of nanomedicines are successfully predicted based on intracellular nanoparticle exposure rather than the overall accumulation in tumour mass. This nonlinear optical nanotechnology offers a valuable imaging tool to evaluate the tumour targeting of new nanomedicines and stratify patients for personalised cancer therapy.

Introduction: The Bioavailability Gap

For decades, the "Enhanced Permeability and Retention" (EPR) effect has served as the foundational principle of cancer nanomedicine. The theory suggests that nanoparticles naturally accumulate in tumors due to their leaky vasculature. However, clinical outcomes have remained inconsistent. This research, published in Nature Communications, argues that the field has been measuring the wrong metric: total tumor accumulation.

A tumor is a complex environment comprising blood vessels and an extracellular matrix. Nanoparticles sequestered in the matrix are effectively "parked" and cannot reach intracellular targets like DNA. This "bioavailability gap" explains why patients with similar levels of total drug accumulation can experience vastly different therapeutic results.

Methods: The Binary Ratiometric Nanoreporter (BiRN)

To bridge this gap, researchers engineered the Binary Ratiometric Nanoreporter (BiRN). This two-modular polymer system acts as a digital switch to isolate the signal of internalized particles.

  • Module 1 (Always-ON): A near-infrared fluorophore that serves as a constant internal standard for tracking.
  • Module 2 (OFF-ON): A pH-sensitive fluorophore that remains dark in the bloodstream and extracellular space (pH ~6.8) but "switches on" when the pH drops below 6.3—a transition that occurs within minutes of endocytosis.
The BiRN mechanism: A sharp pH-sensitive switch generates a binary output (0/1) to isolate the signal from internalized nanoparticles.

By calculating the ratio between these signals (the "O/A signal"), the system generates a digitized output: 0 for extracellular space and 1 for intracellular space. This effectively removes the "noise" of particles that have reached the tumor but are not yet bioavailable.

Key Results: The "20% Rule" and Predictive Power

The study utilized various models, including A549 lung and 4T1 breast cancer lines, as well as Patient-Derived Xenografts (PDX). The findings revealed a stark reality: across different tumor types, only 10.7% to 28.2% of accumulated nanoparticles were actually internalized. The vast majority remained trapped in acellular regions.

Crucially, the researchers found that total accumulation is a poor proxy for success. Instead, therapeutic response correlated strongly with the BiRN intracellular signal. For the paclitaxel prodrug PDPA-PTX, the correlation between intracellular exposure and tumor inhibition was remarkably high (R = 0.8636, p < 0.0001).

Tumor volume change over time for 'High' vs 'Low' endocytosis groups, demonstrating the predictive power of intracellular nanoparticle quantification.

Using BiRN as a companion diagnostic, the team stratified mice into "high" and "low" endocytosis groups. The "high" group showed significantly better tumor suppression and fewer metastases when treated with Doxil, proving that intracellular quantification can predict which patients will respond to treatment.

Discussion and Future Outlook

While the BiRN system provides a powerful tool for patient stratification, it faces limitations regarding optical depth in human subjects. The authors suggest that the underlying ratiometric logic could be adapted for deeper-penetrating modalities like PET or MRI. By shifting the focus from total tumor accumulation to true intracellular bioavailability, this technology paves the way for more effective, personalized nanotherapies.

Summary updated

Abstract

Nanoparticle internalisation is crucial for the precise delivery of drug/genes to its intracellular targets. Conventional quantification strategies can provide the overall profiling of nanoparticle biodistribution, but fail to unambiguously differentiate the intracellularly bioavailable particles from those in tumour intravascular and extracellular microenvironment. Herein, we develop a binary ratiometric nanoreporter (BiRN) that can specifically convert subtle pH variations involved in the endocytic events into digitised signal output, enabling the accurately quantifying of cellular internalisation without introducing extracellular contributions. Using BiRN technology, we find only 10.7-28.2% of accumulated nanoparticles are internalised into intracellular compartments with high heterogeneity within and between different tumour types. We demonstrate the therapeutic responses of nanomedicines are successfully predicted based on intracellular nanoparticle exposure rather than the overall accumulation in tumour mass. This nonlinear optical nanotechnology offers a valuable imaging tool to evaluate the tumour targeting of new nanomedicines and stratify patients for personalised cancer therapy.
BibTeX
@inproceedings{yin2021quantitative,
  author = {Qingqing Yin and Anni Pan and Binlong Chen and Zenghui Wang and Mingmei Tang and Yue Yan and Yaoqi Wang and Heming Xia and Wei Chen and Hongliang Du and Meifang Chen and Chuanxun Fu and Yanni Wang and Xia Yuan and Zhihao Lü and Qiang Zhang and Yiguang Wang},
  title = {{Quantitative imaging of intracellular nanoparticle exposure enables prediction of nanotherapeutic efficacy}},
  booktitle = {Nature Communications},
  year = {2021},
  doi = {10.1038/s41467-021-22678-z},
}
Figure